Hexarelin: What the Evidence Actually Shows

Hexarelin is sold in the peptide-research market as the most potent member of the GHRP family — a stronger GH pulse than GHRP-2 or GHRP-6, per its marketing, with an added "cardioprotective" claim that shows up on nearly every product page. That cardioprotective claim is real, in the specific and limited sense that it's a genuine, actively-published research finding — checked directly against the current literature, it's also entirely an animal finding so far, not a demonstrated human benefit.

What it actually is

Hexarelin — His-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2 — is a synthetic hexapeptide structurally related to GHRP-6, with chemical modifications (notably a 2-methyl-tryptophan substitution) that increase its potency and receptor binding¹. It activates the same ghrelin receptor (GHSR-1a) as GHRP-2 and GHRP-6, the two compounds it's most often compared and sold alongside. A direct human head-to-head study measured this precisely: 1 and 2 micrograms/kg IV hexarelin produced a GH response in six healthy young adults statistically indistinguishable from the same doses of GHRP-2, and both were significantly stronger than a standard IV GHRH dose — but neither compound was fully receptor-specific, each also raising prolactin, ACTH, and cortisol to a degree comparable to a direct corticotropin-releasing-hormone challenge². That non-specificity — GH release alongside a broader hormonal response — is a real, measured property of this compound, not a hypothetical concern.

The cardioprotective claim: real, and entirely preclinical so far

This is the single most-repeated marketing claim for hexarelin, and it deserves to be reported at the precision the actual literature earns rather than the confidence the marketing copy implies. Checked directly against a 2026 peer-reviewed review of this exact peptide class, the finding is stated plainly: "preclinical literature describes potential cardioprotective actions — such as reduced infarct size and protection of cardiomyocytes under ischaemic conditions, but these findings derive from animal and in vitro models and currently lack confirmatory evidence from human clinical trials¹." That is a real, published research thread — rodent myocardial-infarction models and cultured cardiomyocyte experiments have repeatedly found hexarelin reduces infarct size, preserves cardiac function, and protects heart-muscle cells from induced apoptosis — and it is, as of this review, an animal-and-cell-culture finding with no confirmed human cardioprotection trial behind it. This article states both halves together: the preclinical signal is real and repeated across multiple independent studies; the human confirmation does not yet exist.

The real human dosing literature — and a genuine route surprise

Hexarelin's actual published human research is smaller and more specific than the "cardioprotective GH secretagogue" marketing suggests, and it holds a real surprise worth stating directly: the chronic human dosing studies located for this article did not use injection. A 1996 controlled study in elderly adults (aged 63-80) tested two separate chronic regimens: an 8-day course of intranasal hexarelin (1.25 mg three times daily) in seven subjects, and a separate 15-day course of oral hexarelin (20 mg three times daily) in seven more³. Both routes produced a real, measurable GH response comparable to a standard IV GHRH dose, and — the study's own central finding — neither showed the desensitization (a blunted response to repeated dosing) that continuous GHRP infusion is known to cause; intermittent dosing by either route preserved the GH response across the full treatment course, and both routes produced a small but statistically significant rise in IGFBP-3³. A separate pediatric growth-disorder study, cited in the same 2026 review, used several months of chronic intranasal hexarelin and found real increases in IGF-1 and changes in body-fat measurements in that specific clinical population¹ — again not injection. Set against that, the acute, single-dose GH-stimulation literature — the same head-to-head study already discussed above — used IV administration for a one-time diagnostic-style challenge². Put plainly: the real published human hexarelin literature splits by purpose — IV for a single acute test, oral or intranasal for actual chronic dosing regimens — which does not map neatly onto "this is an injectable peptide" the way some other compounds in this corpus do.

The regulatory picture — genuinely different from its two siblings in this batch

Checked live and directly, rather than assumed to match GHRP-2 and GHRP-6: a full-text search of FDA's current 503A Bulks List (the May 14, 2026 PDF) and FDA's companion significant-safety-risks page found zero mention of hexarelin in either document. That is a real, specific, and different regulatory posture from both GHRP-2 and GHRP-6, which sit in Category 3 of the 503A list and carry dated entries on the safety-risks page — hexarelin has never been formally nominated for FDA's compounding-substance review process at all, at least as far as either current document shows. Separately, DailyMed's structured-product-label search returns zero results for "hexarelin" — no FDA-approved U.S. human drug product exists, and hexarelin was never pursued through the U.S. approval process the way GHRP-2's Japanese diagnostic-use counterpart pralmorelin was. openFDA's FAERS database returns 1 total report for "HEXARELIN," live-queried for this article — the smallest adverse-event count of the three GHRP-family compounds covered in this batch, though a low FAERS count reflects reporting volume rather than confirmed safety.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell hexarelin — this site's own identity-layer research confirms it is not tagged to any reviewed seller. Hexarelin's real evidence base is genuinely specific: a confirmed, potent, non-specific GH-releasing mechanism in humans (matched closely by GHRP-2 in the one direct comparison study located), a real and repeated cardioprotective signal that remains animal-and-cell-culture-only as of this review, and a chronic human dosing literature that actually used oral and intranasal routes rather than injection. Our reconstitution calculator does the vial-to-syringe arithmetic for readers using an injectable product, following the acute-testing and broader GHRP-class research pattern — but the honest published chronic-dosing record for this specific compound points to oral and intranasal administration, a distinction worth knowing before assuming any particular product form matches what was actually studied. Readers comparing this compound against its closest relatives can find our GHRP-2 evidence review and our GHRP-6 evidence review here, and our CJC-1295/Ipamorelin evidence review covers the newer-generation compound engineered specifically for the receptor selectivity this older GHRP class lacks.